1-anilino-8-naphthalenesulfonate has been researched along with Weight Loss in 95 studies
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd
8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.
Weight Loss: Decrease in existing BODY WEIGHT.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It is well established that combining a reduced calorie, low-fat diet with the lipase inhibitor orlistat results in significantly greater weight loss than placebo plus diet." | 9.15 | Pragmatic study of orlistat 60 mg on abdominal obesity. ( Beaver, JD; Bell, JD; Berk, ES; Delafont, B; Frost, G; Gambarota, G; Makwana, A; Matthews, PM; Mishra, RG; Newbould, R; Rao, AW; Schwartz, SM; Thomas, EL, 2011) |
| "Cetilistat produced a clinically and statistically significant weight loss in obese patients in this short-term 12-week study." | 9.12 | Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. ( Bryson, A; Hickling, R; Kopelman, P; Rissanen, A; Rossner, S; Toubro, S; Valensi, P, 2007) |
| "The present study shows that both sibutramine-induced and orlistat-induced weight losses result in reduction of insulin resistance, and improvements in biochemical markers and US findings of NASH." | 9.10 | The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. ( Karaoglanoglu, M; Kilic, FB; Nazligul, Y; Sabuncu, T; Ucar, E, 2003) |
| "Orlistat is a useful and an effective therapy in obese diabetic patients, promoting clinically significant weight loss and improved glycaemic control and lipid profile." | 9.10 | Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. ( Aschner, P; Barranco, J; Gross, J; Halpern, A; Jadzinsky, M; Mancini, MC; Matos, AG; Ramirez, L; Repetto, G; Suplicy, H; Zanella, MT, 2003) |
| "This study demonstrates the effectiveness of an intervention combining orlistat and lifestyle modification with Mexican-American women, a population with substantial risk for obesity." | 9.10 | Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification. ( Balasubramanyam, A; Foreyt, JP; Haddock, CK; Poston, WS; Reeves, RS; Satterwhite, O; Stormer, S; Taylor, JE, 2003) |
| "Orlistat as an adjunct to dietary intervention promotes weight loss and reduces LDL-C beyond the effect of weight loss in overweight or obese patients with concomitant hypercholesterolemia." | 9.09 | The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. ( Kolanowski, J; Muls, E; Scheen, A; Van Gaal, L, 2001) |
| "Orlistat, an intestinal lipase inhibitor, has recently been approved by the US Food and Drug Administration for treatment of obesity." | 9.09 | Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss. ( Cockey, L; Everson, GT; Guerciolini, R; Häeussler, J; McKinley, C; Pace, DG; Showalter, R; Trouillot, TE; Zhi, J, 2001) |
| "This study describes the changes in risk factors for coronary heart disease in obese persons with syndrome X after orlistat-assisted weight loss." | 9.09 | Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. ( Boldrin, M; Hauptman, J; Lucas, C; Reaven, G; Segal, K, 2001) |
| "Orlistat is a gastrointestinal lipase inhibitor that reduces dietary fat absorption by approximately 30%, promotes weight loss, and may reduce the risk of developing impaired glucose tolerance and type 2 diabetes in obese subjects." | 9.09 | Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. ( Boldrin, MN; Hauptman, J; Heymsfield, SB; Lucas, CP; Rissanen, A; Segal, KR; Sjöström, L; Wilding, JP, 2000) |
| "Primary efficacy criterion was the difference in weight loss after 12 weeks of treatment between the Orlistat treated groups and the diet alone group." | 9.08 | Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. ( Czubayko, F; Drent, ML; Larsson, I; Quaade, F; Sjöström, L; Strobel, W; van der Veen, EA; von Bergmann, K; William-Olsson, T, 1995) |
| "We undertook a randomised controlled trial to assess the efficacy and tolerability of orlistat, a gastrointestinal lipase inhibitor, in promoting weight loss and preventing weight regain in obese patients over a 2-year period." | 9.08 | Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. ( Andersen, T; Boldrin, M; Golay, A; Koppeschaar, HP; Krempf, M; Rissanen, A; Sjöström, L, 1998) |
| " Published data suggest that orlistat 120 mg, a lipase inhibitor used to treat obesity, may improve glycaemic parameters through weight loss-independent effects." | 8.85 | Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. ( Hauptman, J; Jacob, S; Meier, MK; Rabbia, M, 2009) |
| "Treatment with cetilistat 80 or 120 mg t." | 6.75 | Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). ( Bryson, A; Groot, Gde H; Hallam, R; Hickling, RI; Kopelman, P; Palmer, R; Rissanen, A; Rossner, S; Toubro, S, 2010) |
| "Obesity is the most common health problem in developed countries." | 6.71 | Influence of intense multidisciplinary follow-up and orlistat on weight reduction in a primary care setting. ( Feigenbaum, A; Pasternak, S; Sarid, M; Vinker, S; Zusk, E, 2005) |
| "Recently however, obesity has been rated by the WHO as an unique disease, resulting in elevated morbidity and mortality." | 6.69 | [Reduction of obesity and improvement in metabolic parameters by inhibition of intestinal lipases: current results with orlistat]. ( Marhardt, K; Toplak, H, 1998) |
| "Orlistat treatment improves oxysterol metabolism in overweight and obese adults." | 5.51 | The Effect of Orlistat on Sterol Metabolism in Obese Patients. ( Choi, MH; Kwon, GE; Kwon, YJ; Lee, HS; Lee, JW, 2022) |
| "Rats treated with gingerol and fed a HFD showed significantly (P < 0." | 5.40 | Anti-obesity action of gingerol: effect on lipid profile, insulin, leptin, amylase and lipase in male obese rats induced by a high-fat diet. ( Deepa, MA; Ponmurugan, P; Saravanan, G; Senthilkumar, B, 2014) |
| "Cetilistat is a novel, orally active, gastrointestinal and pancreatic lipase inhibitor." | 5.39 | Cetilistat for the treatment of obesity. ( Gras, J, 2013) |
| " The purpose of the present study was to determine if a 24 week weight loss program with orlistat 60 mg in overweight subjects would produce a greater change in visceral adipose tissue (VAT) as measured by computed tomography (CT) scan, compared to placebo." | 5.15 | Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial. ( Berk, ES; Dev, VB; Greenway, FL; Kapikian, R; McHutchison, J; Schwartz, SM; Smith, SR; Stenlof, KS, 2011) |
| "It is well established that combining a reduced calorie, low-fat diet with the lipase inhibitor orlistat results in significantly greater weight loss than placebo plus diet." | 5.15 | Pragmatic study of orlistat 60 mg on abdominal obesity. ( Beaver, JD; Bell, JD; Berk, ES; Delafont, B; Frost, G; Gambarota, G; Makwana, A; Matthews, PM; Mishra, RG; Newbould, R; Rao, AW; Schwartz, SM; Thomas, EL, 2011) |
| " The use of the pancreatic lipase inhibitor Orlistat can help seriously overweight people to achieve and maintain weight loss." | 5.14 | Effect of orlistat on the total ghrelin and leptin levels in obese patients. ( Aydin, S; Donder, E; Koca, SS; Ozkan, B; Ozkan, Y; Sahin, I, 2009) |
| "To investigate the effects of: I) short- (8 weeks), II) long-term (3 years) weight loss, and III) the degree of weight loss on circulating levels of adiponectin, high sensitive-C reactive protein (hs-CRP), and fibrinogen in obese subjects." | 5.13 | Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. ( Bruun, JM; Hougaard, DM; Madsen, EL; Richelsen, B; Rissanen, A; Skogstrand, K; Tonstad, S, 2008) |
| "Cetilistat produced a clinically and statistically significant weight loss in obese patients in this short-term 12-week study." | 5.12 | Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. ( Bryson, A; Hickling, R; Kopelman, P; Rissanen, A; Rossner, S; Toubro, S; Valensi, P, 2007) |
| " Orlistat, a potent lipase inhibitor, induces fat malabsorption and body weight loss but might accelerate gastric emptying as a result of suppressed CCK release." | 5.12 | Influences of fat restriction and lipase inhibition on gastric emptying in obesity. ( Bennink, RJ; Mathus-Vliegen, EM; van Ierland-van Leeuwen, ML, 2006) |
| "Orlistat is a useful and an effective therapy in obese diabetic patients, promoting clinically significant weight loss and improved glycaemic control and lipid profile." | 5.10 | Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. ( Aschner, P; Barranco, J; Gross, J; Halpern, A; Jadzinsky, M; Mancini, MC; Matos, AG; Ramirez, L; Repetto, G; Suplicy, H; Zanella, MT, 2003) |
| "The present study shows that both sibutramine-induced and orlistat-induced weight losses result in reduction of insulin resistance, and improvements in biochemical markers and US findings of NASH." | 5.10 | The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. ( Karaoglanoglu, M; Kilic, FB; Nazligul, Y; Sabuncu, T; Ucar, E, 2003) |
| "This study demonstrates the effectiveness of an intervention combining orlistat and lifestyle modification with Mexican-American women, a population with substantial risk for obesity." | 5.10 | Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification. ( Balasubramanyam, A; Foreyt, JP; Haddock, CK; Poston, WS; Reeves, RS; Satterwhite, O; Stormer, S; Taylor, JE, 2003) |
| "Orlistat is a gastrointestinal lipase inhibitor that reduces dietary fat absorption by approximately 30%, promotes weight loss, and may reduce the risk of developing impaired glucose tolerance and type 2 diabetes in obese subjects." | 5.09 | Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. ( Boldrin, MN; Hauptman, J; Heymsfield, SB; Lucas, CP; Rissanen, A; Segal, KR; Sjöström, L; Wilding, JP, 2000) |
| "This study describes the changes in risk factors for coronary heart disease in obese persons with syndrome X after orlistat-assisted weight loss." | 5.09 | Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. ( Boldrin, M; Hauptman, J; Lucas, C; Reaven, G; Segal, K, 2001) |
| "Orlistat, an intestinal lipase inhibitor, has recently been approved by the US Food and Drug Administration for treatment of obesity." | 5.09 | Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss. ( Cockey, L; Everson, GT; Guerciolini, R; Häeussler, J; McKinley, C; Pace, DG; Showalter, R; Trouillot, TE; Zhi, J, 2001) |
| "Orlistat as an adjunct to dietary intervention promotes weight loss and reduces LDL-C beyond the effect of weight loss in overweight or obese patients with concomitant hypercholesterolemia." | 5.09 | The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. ( Kolanowski, J; Muls, E; Scheen, A; Van Gaal, L, 2001) |
| "In addition to better weight loss and maintenance of reduced weight, orlistat treatment is associated with beneficial changes in body composition but with no excess decrease in resting energy expenditure as compared to that achieved during placebo with a dietary therapy alone." | 5.09 | Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. ( Franssila-Kallunki, A; Karhunen, L; Kolehmainen, M; Rissanen, A; Rissanen, P; Uusitupa, M; Valve, R, 2000) |
| "Two-year treatment with orlistat plus diet significantly promotes weight loss, lessens weight regain, and improves some obesity-related disease risk factors." | 5.09 | Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. ( Chung, J; Davidson, MH; DiGirolamo, M; Foreyt, JP; Halsted, CH; Hauptman, J; Heber, D; Heimburger, DC; Heymsfield, SB; Lucas, CP; Robbins, DC, 1999) |
| "The use of orlistat during periods of attempted weight maintenance minimizes weight readjustment and facilitates long-term improvement in obesity-related disease risk factors." | 5.09 | Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. ( Anderson, JW; Aronne, LJ; Fujioka, K; Hauptman, J; Hill, JO; O'Neil, PM; Smith, DK; Zavoral, JH, 1999) |
| "Primary efficacy criterion was the difference in weight loss after 12 weeks of treatment between the Orlistat treated groups and the diet alone group." | 5.08 | Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. ( Czubayko, F; Drent, ML; Larsson, I; Quaade, F; Sjöström, L; Strobel, W; van der Veen, EA; von Bergmann, K; William-Olsson, T, 1995) |
| "We undertook a randomised controlled trial to assess the efficacy and tolerability of orlistat, a gastrointestinal lipase inhibitor, in promoting weight loss and preventing weight regain in obese patients over a 2-year period." | 5.08 | Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. ( Andersen, T; Boldrin, M; Golay, A; Koppeschaar, HP; Krempf, M; Rissanen, A; Sjöström, L, 1998) |
| " Published data suggest that orlistat 120 mg, a lipase inhibitor used to treat obesity, may improve glycaemic parameters through weight loss-independent effects." | 4.85 | Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. ( Hauptman, J; Jacob, S; Meier, MK; Rabbia, M, 2009) |
| "Currently, the substances orlistat and sibutramine are approved drugs for the pharmacotherapy of obesity." | 4.83 | [Pharmacotherapy in the treatment of obesity]. ( Hamann, A, 2006) |
| " Orlistat, a lipase inhibitor, in a dose of 50 mg three times a day leads to a significant increase in weight loss compared to placebo in moderately obese people." | 4.79 | First clinical studies with orlistat: a short review. ( Drent, ML; van der Veen, EA, 1995) |
| "It was demonstrated that the anti-obesity effects of oolong tea in high-fat diet-treated mice might be due partly to the enhancing effect of caffeine isolated from oolong tea on noradrenaline-induced lipolysis in adipose tissue, and to the inhibitory action of some other substance in oolong tea on pancreatic lipase activity." | 3.70 | Anti-obesity action of oolong tea. ( Han, LK; Kimura, Y; Li, J; Okuda, H; Takaku, T, 1999) |
| "Weight loss was followed by a significant increase of plasma levels of PYY and GLP-1 in group treated with orlistat, and was about 2-times greater than receiving placebo." | 2.78 | Long-term inhibition of intestinal lipase by orlistat improves release of gut hormones increasing satiety in obese women. ( Chudek, J; Dąbrowski, P; Janowska, J; Jonderko, K; Kocełak, P; Olszanecka-Glinianowicz, M; Smertka, M, 2013) |
| "Weight loss is effective in decreasing liver fat in subjects who are homozygous for the rs738409 PNPLA3 G or C allele." | 2.76 | Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. ( Ferrannini, E; Gastaldelli, A; Hakkarainen, A; Kotronen, A; Lundbom, J; Lundbom, N; Olkkonen, VM; Orho-Melander, M; Perttilä, J; Rissanen, A; Sevastianova, K; Suojanen, L; Yki-Järvinen, H, 2011) |
| "Treatment with cetilistat 80 or 120 mg t." | 2.75 | Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). ( Bryson, A; Groot, Gde H; Hallam, R; Hickling, RI; Kopelman, P; Palmer, R; Rissanen, A; Rossner, S; Toubro, S, 2010) |
| "Obesity is the most common health problem in developed countries." | 2.71 | Influence of intense multidisciplinary follow-up and orlistat on weight reduction in a primary care setting. ( Feigenbaum, A; Pasternak, S; Sarid, M; Vinker, S; Zusk, E, 2005) |
| "Recently however, obesity has been rated by the WHO as an unique disease, resulting in elevated morbidity and mortality." | 2.69 | [Reduction of obesity and improvement in metabolic parameters by inhibition of intestinal lipases: current results with orlistat]. ( Marhardt, K; Toplak, H, 1998) |
| "Orlistat (Ro 18-0647) is an inhibitor of gastric, carboxylester and pancreatic lipase and specifically reduces the absorption of dietary fat due to the inhibition of triglyceride hydrolysis." | 2.67 | Lipase inhibition: a novel concept in the treatment of obesity. ( Drent, ML; van der Veen, EA, 1993) |
| "The prevalence of Type 2 diabetes is expected to increase in parallel with obesity rates and the ageing population." | 2.52 | Practical approach to non-alcoholic fatty liver disease in patients with diabetes. ( Alazawi, W; Syn, WK; Tai, FW, 2015) |
| "Obesity is one of the greatest public health challenges of the twenty-first century." | 2.45 | Current pharmacotherapeutic concepts for the treatment of obesity in adults. ( Idelevich, E; Kirch, W; Schindler, C, 2009) |
| "Orlistat is a new inhibitor of pancreatic lipase enzyme." | 2.40 | New aspects in the management of obesity: operation and the impact of lipase inhibitors. ( Uusitupa, M, 1999) |
| " A multifaceted approach to the obese patient should include identifying potential causes for weight gain, outlining medical conditions that would benefit by weight loss, and tailoring a weight loss program that is safe and effective for the individual." | 2.40 | Safe and effective management of the obese patient. ( Collazo-Clavell, ML, 1999) |
| "Cachexia is the main cause of mortality in advanced cancer patients." | 1.46 | Insulin, not glutamine dipeptide, reduces lipases expression and prevents fat wasting and weight loss in Walker 256 tumor-bearing rats. ( Bazotte, RB; Carpinelli, ÂR; da Silva, FG; de Fatima Silva, F; de Morais, H; de Souza, HM; Graciano, MFR; Martins, MIL; Mazucco, TL; Silva, MO, 2017) |
| "Obesity is the major trigger of nonalcoholic fatty liver disease (NAFLD)." | 1.43 | PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery. ( Alustiza, JM; Banales, JM; Bujanda, L; Emparanza, JI; Jiménez-Agüero, R; Krawczyk, M; Lammert, F; Perugorria, MJ, 2016) |
| "Cancer cachexia is a debilitating condition that impacts patient morbidity, mortality, and quality of life and for which effective therapies are lacking." | 1.42 | Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. ( Bekaii-Saab, T; Bloomston, M; Chen, CS; Frankhouser, DE; Guttridge, DC; He, WA; Hsu, EC; Kulp, SK; Lai, IL; Lesinski, GB; Marcucci, G; Mo, X; Tseng, YC; Yan, PS, 2015) |
| "Rats treated with gingerol and fed a HFD showed significantly (P < 0." | 1.40 | Anti-obesity action of gingerol: effect on lipid profile, insulin, leptin, amylase and lipase in male obese rats induced by a high-fat diet. ( Deepa, MA; Ponmurugan, P; Saravanan, G; Senthilkumar, B, 2014) |
| "Cetilistat is a novel, orally active, gastrointestinal and pancreatic lipase inhibitor." | 1.39 | Cetilistat for the treatment of obesity. ( Gras, J, 2013) |
| "Obesity is highly associated with elevated serum triglycerides, hepatic steatosis and type 2 diabetes (T2D)." | 1.38 | Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. ( Adiels, M; Borén, J; Burch, L; Burza, MA; Carlsson, LM; Colhoun, H; Dillon, JF; Doney, AS; Donnelly, LA; Frayling, T; Hattersley, AT; Jacobson, P; Maglio, C; McCarthy, M; Morris, AD; Palmer, CN; Pearson, ER; Peltonen, M; Pirazzi, C; Romeo, S; Sjöström, L; Svensson, PA, 2012) |
| "Cachexia is a multifactorial wasting syndrome most common in patients with cancer that is characterized by the uncontrolled loss of adipose and muscle mass." | 1.37 | Adipose triglyceride lipase contributes to cancer-associated cachexia. ( Das, SK; Diwoky, C; Eder, S; Gorkiewicz, G; Guertl, B; Haemmerle, G; Hoefler, G; Kumari, P; Schauer, S; Tamilarasan, KP; Temmel, H; Trauner, M; Vesely, P; Zechner, R; Zimmermann, R, 2011) |
| "Obesity is associated with lipid abnormalities leading to an increased morbidity and mortality from atherosclerotic disease." | 1.35 | Effects of weight loss on lipid transfer proteins in morbidly obese women. ( Aigner, F; Ebenbichler, CF; Engl, J; Kaser, S; Laimer, MW; Patsch, JR; Rauchenzauner, M; Ritsch, A; Tatarczyk, T; Tschoner, A; Weiss, H, 2009) |
| "Sibutramine is a centrally acting serotonin/noradrenaline reuptake inhibitor that mainly increases satiety." | 1.35 | [Pharmacological therapy of obesity]. ( Pagotto, U; Pasquali, R; Vanuzzo, D; Vicennati, V, 2008) |
| "Obesity is associated with increased triacylglycerol (TAG) storage in adipose tissue and insulin resistance." | 1.34 | Adipose triglyceride lipase and hormone-sensitive lipase protein expression is decreased in the obese insulin-resistant state. ( Arner, P; Blaak, EE; Holm, C; Hul, GB; Jocken, JW; Langin, D; Saris, WH; Smit, E; Valle, C, 2007) |
| "(1) The treatment of obesity is based on calorie reduction and moderate physical activity." | 1.33 | Rimonabant: new drug. Obesity: loss of a few kilos, many questions. ( , 2006) |
| "We evaluated 32 patients with Type 2 diabetes who underwent such course of treatment, with view of establishing whether the interruption has any detrimental effect on the success of the therapy in terms of weight loss and diabetes compensation." | 1.33 | The effects of orlistat treatment interruption on weight and associated metabolic parameters. ( Owen, K; Svacina, S, 2006) |
| "Treatment with orlistat for 16 weeks was followed by a significant fall of BMI and MAP, insulinemia, insulin/glucose ratio, leptinemia, serum total cholesterol, triglycerides, HDL-cholesterol and 25-OH-D concentration respectively." | 1.32 | [Effect of orlistat therapy on carbohydrate, lipid, vitamin and hormone plasma levels in obese subjects]. ( Czerwieńska, B; Franek, E; Irzyniec, T; Kokot, F; Wiecek, A, 2004) |
| "Weight loss is not required to increase HDL-C with exercise training in overweight men, but without weight loss, even prolonged exercise training produces only modest changes in HDL-C concentrations." | 1.30 | Effect of prolonged exercise training without weight loss on high-density lipoprotein metabolism in overweight men. ( Bausserman, L; Flynn, MM; Herbert, PN; Saritelli, A; Spannaus-Martin, D; Thompson, PD; Yurgalevitch, SM; Zmuda, JM, 1997) |
| "(1) Treatments for obesity are disappointing." | 1.30 | Orlistat: new preparation. No hurry . . . ( , 1999) |
| "Ninety-two patients in long-term treatment for obesity completed a questionnaire on the weight development of their close family members." | 1.29 | Effects of weight reduction programs on close family members. ( Franson, K; Rössner, S, 1994) |
| "Weight loss was maintained throughout the study, which lasted 24 weeks." | 1.28 | Relationships between the amount of weight loss and post-heparin lipoprotein lipase activity in patients with type II diabetes. ( Darga, LL; Holden, JH; Jen, KL; Kasim, SE; Khilnani, S; Lucas, CP; Patton, S, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.05) | 18.7374 |
| 1990's | 24 (25.26) | 18.2507 |
| 2000's | 39 (41.05) | 29.6817 |
| 2010's | 28 (29.47) | 24.3611 |
| 2020's | 3 (3.16) | 2.80 |
| Authors | Studies |
|---|---|
| Kwon, YJ | 1 |
| Kwon, GE | 1 |
| Lee, HS | 1 |
| Choi, MH | 1 |
| Lee, JW | 1 |
| Abdelrahman, A | 1 |
| Kumstel, S | 1 |
| Zhang, X | 1 |
| Liebig, M | 1 |
| Wendt, EHU | 1 |
| Eichberg, J | 1 |
| Palme, R | 1 |
| Thum, T | 1 |
| Vollmar, B | 1 |
| Zechner, D | 1 |
| Liu, TT | 1 |
| Liu, XT | 1 |
| Chen, QX | 1 |
| Shi, Y | 1 |
| Amin, M | 1 |
| Bhatti, HN | 1 |
| Nawaz, S | 1 |
| Bilal, M | 1 |
| de Morais, H | 1 |
| de Fatima Silva, F | 1 |
| da Silva, FG | 1 |
| Silva, MO | 1 |
| Graciano, MFR | 1 |
| Martins, MIL | 1 |
| Carpinelli, ÂR | 1 |
| Mazucco, TL | 1 |
| Bazotte, RB | 1 |
| de Souza, HM | 1 |
| Aruga, M | 1 |
| Tokita, Y | 1 |
| Nakajima, K | 1 |
| Kamachi, K | 1 |
| Tanaka, A | 1 |
| Verhoef, SP | 1 |
| Camps, SG | 1 |
| Bouwman, FG | 2 |
| Mariman, EC | 2 |
| Westerterp, KR | 1 |
| Wang, P | 1 |
| van Baak, M | 1 |
| Saris, WH | 2 |
| Marzuillo, P | 1 |
| Grandone, A | 1 |
| Perrone, L | 1 |
| del Giudice, EM | 1 |
| Olszanecka-Glinianowicz, M | 1 |
| Dąbrowski, P | 1 |
| Kocełak, P | 1 |
| Janowska, J | 1 |
| Smertka, M | 1 |
| Jonderko, K | 1 |
| Chudek, J | 1 |
| Gras, J | 1 |
| Saravanan, G | 1 |
| Ponmurugan, P | 1 |
| Deepa, MA | 1 |
| Senthilkumar, B | 1 |
| Tai, FW | 1 |
| Syn, WK | 1 |
| Alazawi, W | 1 |
| Xu, M | 1 |
| Ng, SS | 1 |
| Bray, GA | 2 |
| Ryan, DH | 1 |
| Sacks, FM | 1 |
| Ning, G | 1 |
| Qi, L | 1 |
| Tseng, YC | 1 |
| Kulp, SK | 1 |
| Lai, IL | 1 |
| Hsu, EC | 1 |
| He, WA | 1 |
| Frankhouser, DE | 1 |
| Yan, PS | 1 |
| Mo, X | 1 |
| Bloomston, M | 1 |
| Lesinski, GB | 1 |
| Marcucci, G | 1 |
| Guttridge, DC | 1 |
| Bekaii-Saab, T | 1 |
| Chen, CS | 1 |
| Karki, S | 1 |
| Farb, MG | 1 |
| Myers, S | 1 |
| Apovian, C | 1 |
| Hess, DT | 1 |
| Gokce, N | 1 |
| Chen, YL | 1 |
| Zhu, S | 1 |
| Zhang, L | 1 |
| Feng, PJ | 1 |
| Yao, XK | 1 |
| Qian, CG | 1 |
| Zhang, C | 1 |
| Jiang, XQ | 1 |
| Shen, QD | 1 |
| Wieser, V | 1 |
| Adolph, TE | 1 |
| Enrich, B | 1 |
| Moser, P | 1 |
| Moschen, AR | 1 |
| Tilg, H | 1 |
| Krawczyk, M | 1 |
| Jiménez-Agüero, R | 1 |
| Alustiza, JM | 1 |
| Emparanza, JI | 1 |
| Perugorria, MJ | 1 |
| Bujanda, L | 1 |
| Lammert, F | 1 |
| Banales, JM | 1 |
| Campbell, JA | 1 |
| Sanders, DS | 1 |
| Francis, KA | 1 |
| Kurien, M | 1 |
| Lee, S | 1 |
| Taha, H | 1 |
| Ramadas, A | 1 |
| Joy, D | 1 |
| Hopper, AD | 1 |
| Lasa, A | 1 |
| Churruca, I | 1 |
| Simón, E | 1 |
| Fernández-Quintela, A | 1 |
| Rodríguez, VM | 1 |
| Portillo, MP | 1 |
| Martins, AM | 1 |
| Pham, QP | 1 |
| Malafaya, PB | 1 |
| Sousa, RA | 1 |
| Gomes, ME | 1 |
| Raphael, RM | 1 |
| Kasper, FK | 1 |
| Reis, RL | 1 |
| Mikos, AG | 1 |
| Pagotto, U | 1 |
| Vanuzzo, D | 1 |
| Vicennati, V | 1 |
| Pasquali, R | 1 |
| Idelevich, E | 1 |
| Kirch, W | 1 |
| Schindler, C | 1 |
| Jacob, S | 1 |
| Rabbia, M | 1 |
| Meier, MK | 1 |
| Hauptman, J | 7 |
| Kopelman, P | 2 |
| Groot, Gde H | 1 |
| Rissanen, A | 8 |
| Rossner, S | 3 |
| Toubro, S | 2 |
| Palmer, R | 1 |
| Hallam, R | 1 |
| Bryson, A | 2 |
| Hickling, RI | 1 |
| Mustonen, AM | 1 |
| Puukka, M | 1 |
| Rouvinen-Watt, K | 1 |
| Aho, J | 1 |
| Asikainen, J | 1 |
| Nieminen, P | 1 |
| Laimer, MW | 1 |
| Engl, J | 1 |
| Tschoner, A | 1 |
| Kaser, S | 1 |
| Ritsch, A | 1 |
| Tatarczyk, T | 1 |
| Rauchenzauner, M | 1 |
| Weiss, H | 1 |
| Aigner, F | 1 |
| Patsch, JR | 1 |
| Ebenbichler, CF | 1 |
| MacLaughlin, HL | 1 |
| Cook, SA | 1 |
| Kariyawasam, D | 1 |
| Roseke, M | 1 |
| van Niekerk, M | 1 |
| Macdougall, IC | 1 |
| Ozkan, Y | 1 |
| Aydin, S | 2 |
| Donder, E | 1 |
| Koca, SS | 1 |
| Ozkan, B | 1 |
| Sahin, I | 1 |
| Mitsuhashi, Y | 1 |
| Nagaoka, D | 1 |
| Ishioka, K | 1 |
| Bigley, KE | 1 |
| Okawa, M | 1 |
| Otsuji, K | 1 |
| Bauer, JE | 1 |
| Kosteli, A | 1 |
| Sugaru, E | 1 |
| Haemmerle, G | 2 |
| Martin, JF | 1 |
| Lei, J | 1 |
| Zechner, R | 2 |
| Ferrante, AW | 1 |
| Sevastianova, K | 2 |
| Kotronen, A | 2 |
| Gastaldelli, A | 1 |
| Perttilä, J | 1 |
| Hakkarainen, A | 2 |
| Lundbom, J | 2 |
| Suojanen, L | 1 |
| Orho-Melander, M | 1 |
| Lundbom, N | 2 |
| Ferrannini, E | 1 |
| Olkkonen, VM | 2 |
| Yki-Järvinen, H | 2 |
| Das, SK | 1 |
| Eder, S | 1 |
| Schauer, S | 1 |
| Diwoky, C | 1 |
| Temmel, H | 1 |
| Guertl, B | 1 |
| Gorkiewicz, G | 1 |
| Tamilarasan, KP | 1 |
| Kumari, P | 1 |
| Trauner, M | 1 |
| Zimmermann, R | 1 |
| Vesely, P | 1 |
| Hoefler, G | 1 |
| Thomas, EL | 1 |
| Makwana, A | 1 |
| Newbould, R | 1 |
| Rao, AW | 1 |
| Gambarota, G | 1 |
| Frost, G | 1 |
| Delafont, B | 1 |
| Mishra, RG | 1 |
| Matthews, PM | 1 |
| Berk, ES | 2 |
| Schwartz, SM | 2 |
| Bell, JD | 1 |
| Beaver, JD | 1 |
| Smith, SR | 1 |
| Stenlof, KS | 1 |
| Greenway, FL | 1 |
| McHutchison, J | 1 |
| Dev, VB | 1 |
| Kapikian, R | 1 |
| Palmer, CN | 1 |
| Maglio, C | 1 |
| Pirazzi, C | 1 |
| Burza, MA | 1 |
| Adiels, M | 1 |
| Burch, L | 1 |
| Donnelly, LA | 1 |
| Colhoun, H | 1 |
| Doney, AS | 1 |
| Dillon, JF | 1 |
| Pearson, ER | 1 |
| McCarthy, M | 1 |
| Hattersley, AT | 1 |
| Frayling, T | 1 |
| Morris, AD | 1 |
| Peltonen, M | 2 |
| Svensson, PA | 1 |
| Jacobson, P | 1 |
| Borén, J | 1 |
| Sjöström, L | 4 |
| Carlsson, LM | 1 |
| Romeo, S | 2 |
| Santos, A | 1 |
| Makkonen, J | 1 |
| Silander, K | 1 |
| Gylling, H | 1 |
| Fielding, BA | 1 |
| Colon-Gonzalez, F | 1 |
| Kim, GW | 1 |
| Lin, JE | 1 |
| Valentino, MA | 1 |
| Waldman, SA | 1 |
| Halpern, A | 1 |
| Mancini, MC | 1 |
| Suplicy, H | 1 |
| Zanella, MT | 1 |
| Repetto, G | 1 |
| Gross, J | 1 |
| Jadzinsky, M | 1 |
| Barranco, J | 1 |
| Aschner, P | 1 |
| Ramirez, L | 1 |
| Matos, AG | 1 |
| Sabuncu, T | 1 |
| Nazligul, Y | 1 |
| Karaoglanoglu, M | 1 |
| Ucar, E | 1 |
| Kilic, FB | 1 |
| Engeli, S | 1 |
| Poston, WS | 1 |
| Reeves, RS | 1 |
| Haddock, CK | 1 |
| Stormer, S | 1 |
| Balasubramanyam, A | 1 |
| Satterwhite, O | 1 |
| Taylor, JE | 1 |
| Foreyt, JP | 2 |
| Mathus-Vliegen, EM | 2 |
| Van Ierland-Van Leeuwen, ML | 2 |
| Terpstra, A | 1 |
| Todorova, B | 1 |
| Kubaszek, A | 1 |
| Pihlajamäki, J | 1 |
| Lindström, J | 1 |
| Eriksson, J | 1 |
| Valle, TT | 1 |
| Hämäläinen, H | 1 |
| Ilanne-Parikka, P | 1 |
| Keinänen-Kiukaanniemi, S | 1 |
| Tuomilehto, J | 1 |
| Uusitupa, M | 3 |
| Laakso, M | 1 |
| Rollet, J | 1 |
| Fox, NJ | 1 |
| Ward, KJ | 1 |
| O'Rourke, AJ | 1 |
| Feigenbaum, A | 1 |
| Pasternak, S | 1 |
| Zusk, E | 1 |
| Sarid, M | 1 |
| Vinker, S | 1 |
| Zhao, HL | 1 |
| Sim, JS | 1 |
| Shim, SH | 1 |
| Ha, YW | 1 |
| Kang, SS | 1 |
| Kim, YS | 1 |
| Chanoine, JP | 1 |
| Hampl, S | 1 |
| Jensen, C | 1 |
| Boldrin, M | 3 |
| Czerwieńska, B | 1 |
| Kokot, F | 1 |
| Franek, E | 1 |
| Irzyniec, T | 1 |
| Wiecek, A | 1 |
| Schulthess, G | 1 |
| Kolyvanos Naumann, U | 1 |
| Käser, L | 1 |
| Vetter, W | 1 |
| Nelson, RH | 1 |
| Miles, JM | 1 |
| Bennink, RJ | 1 |
| Hamann, A | 1 |
| Johnston, TP | 1 |
| Goldberg, IJ | 1 |
| Hickling, R | 1 |
| Valensi, P | 1 |
| Jocken, JW | 1 |
| Langin, D | 1 |
| Smit, E | 1 |
| Valle, C | 1 |
| Hul, GB | 1 |
| Holm, C | 1 |
| Arner, P | 1 |
| Blaak, EE | 1 |
| Owen, K | 1 |
| Svacina, S | 1 |
| Woo, J | 1 |
| Sea, MM | 1 |
| Tong, P | 1 |
| Ko, GT | 1 |
| Lee, Z | 1 |
| Chan, J | 1 |
| Chow, FC | 1 |
| Madsen, EL | 1 |
| Bruun, JM | 1 |
| Skogstrand, K | 1 |
| Tonstad, S | 1 |
| Hougaard, DM | 1 |
| Richelsen, B | 1 |
| Bischoff, A | 1 |
| Drent, ML | 3 |
| Larsson, I | 1 |
| William-Olsson, T | 1 |
| Quaade, F | 1 |
| Czubayko, F | 1 |
| von Bergmann, K | 1 |
| Strobel, W | 1 |
| van der Veen, EA | 3 |
| Franson, K | 1 |
| Katzel, LI | 1 |
| Coon, PJ | 1 |
| Dengel, J | 1 |
| Goldberg, AP | 1 |
| Thompson, PD | 1 |
| Yurgalevitch, SM | 1 |
| Flynn, MM | 1 |
| Zmuda, JM | 1 |
| Spannaus-Martin, D | 1 |
| Saritelli, A | 1 |
| Bausserman, L | 1 |
| Herbert, PN | 1 |
| Toornvliet, AC | 1 |
| Pijl, H | 1 |
| Frölich, M | 1 |
| Westendorp, RG | 1 |
| Meinders, AE | 1 |
| Kataoka, K | 1 |
| DiMagno, EP | 1 |
| Andersen, T | 1 |
| Golay, A | 1 |
| Koppeschaar, HP | 1 |
| Krempf, M | 1 |
| Garrow, J | 1 |
| Toplak, H | 1 |
| Marhardt, K | 1 |
| Zavoral, JH | 2 |
| Davidson, MH | 1 |
| DiGirolamo, M | 1 |
| Halsted, CH | 1 |
| Heber, D | 1 |
| Heimburger, DC | 1 |
| Lucas, CP | 3 |
| Robbins, DC | 1 |
| Chung, J | 1 |
| Heymsfield, SB | 2 |
| Ghaneh, P | 1 |
| Neoptolemos, JP | 1 |
| Han, LK | 1 |
| Takaku, T | 1 |
| Li, J | 1 |
| Kimura, Y | 1 |
| Okuda, H | 1 |
| Hill, JO | 1 |
| Anderson, JW | 1 |
| Fujioka, K | 1 |
| O'Neil, PM | 1 |
| Smith, DK | 1 |
| Aronne, LJ | 1 |
| Collazo-Clavell, ML | 1 |
| Lucas, C | 2 |
| Boldrin, MN | 2 |
| Collins, H | 1 |
| Segal, KR | 2 |
| Wilding, JP | 1 |
| Karhunen, L | 1 |
| Franssila-Kallunki, A | 1 |
| Rissanen, P | 1 |
| Valve, R | 1 |
| Kolehmainen, M | 1 |
| Reaven, G | 1 |
| Segal, K | 1 |
| Trouillot, TE | 1 |
| Pace, DG | 1 |
| McKinley, C | 1 |
| Cockey, L | 1 |
| Zhi, J | 1 |
| Häeussler, J | 1 |
| Guerciolini, R | 1 |
| Showalter, R | 1 |
| Everson, GT | 1 |
| Wittmann, T | 1 |
| Róka, R | 1 |
| Palágyi, P | 1 |
| Czakó, L | 1 |
| Jármay, K | 1 |
| Rosztóczy, A | 1 |
| Lonovics, J | 1 |
| Muls, E | 1 |
| Kolanowski, J | 1 |
| Scheen, A | 1 |
| Van Gaal, L | 1 |
| Shoji, T | 1 |
| Nishizawa, Y | 1 |
| Koyama, H | 1 |
| Hagiwara, S | 1 |
| Aratani, H | 1 |
| Sasao, K | 1 |
| Kishimoto, H | 1 |
| Tanishita, H | 1 |
| Morii, H | 1 |
| Simpson, KW | 1 |
| Simpson, JW | 1 |
| Lake, S | 1 |
| Morton, DB | 1 |
| Batt, RM | 1 |
| Kasim, SE | 1 |
| Darga, LL | 1 |
| Holden, JH | 1 |
| Khilnani, S | 1 |
| Patton, S | 1 |
| Jen, KL | 2 |
| Kasim, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of the Genetic Background Involved in Weight Regain Through Mechanisms Including Energy Expenditure, Physical Activity and Adipogenic Capacity[NCT01015508] | 200 participants (Anticipated) | Interventional | 2010-02-28 | Active, not recruiting | |||
| Double-blind Placebo-controlled Clinical Trial of Ginger (Zingiber Officinale) Addition in the Obesity Treatment and Improvement Behavioral Profile[NCT02742194] | Phase 2 | 84 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| Preventing Overweight Using Novel Dietary Strategies (Pounds Lost)[NCT00072995] | 811 participants | Interventional | 2003-09-30 | Completed | |||
| Effect of a Nutrigenetic Intervention on Blood Lipid Markers and Body Composition of Adults With Overweight and Obesity[NCT05210023] | 101 participants (Actual) | Interventional | 2021-06-09 | Completed | |||
| Multicentre Double Blind Placebo Controlled Parallel Group Dose Ranging Study of ATL-962 to Assess Weight Loss, Safety and Tolerability in Obese Patients With Type II Diabetes Being Treated With Metformin, in Comparison With Orlistat[NCT00156897] | Phase 2 | 600 participants | Interventional | 2004-12-31 | Completed | ||
| Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients[NCT04529278] | Phase 2 | 18 participants (Actual) | Interventional | 2021-01-18 | Active, not recruiting | ||
| Biochemical and Functional Biomarkers of Cachexia in Cancer Patients[NCT03191955] | 120 participants (Anticipated) | Observational | 2015-11-30 | Recruiting | |||
| The Effects of Weight Reduction With Orlistat vs. Placebo on Changes in Body Composition[NCT00752726] | Phase 4 | 131 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)[NCT02783469] | 1,915 participants (Actual) | Observational | 2004-10-31 | Completed | |||
| The Finnish Diabetes Prevention Study: A Follow-up Study on the Effect of a Dietary and Exercise Intervention in the Prevention of Diabetes and Its Vascular Complications[NCT00518167] | 522 participants (Actual) | Interventional | 1993-11-30 | Active, not recruiting | |||
| Safety and Efficacy of Orlistat (Xenical, Hoffmann LaRoche) in African American and Caucasian Children and Adolescents With Obesity-Related Comorbid Conditions[NCT00001723] | Phase 2 | 200 participants (Actual) | Interventional | 1998-05-31 | Completed | ||
| Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease - A Randomized Controlled Trial[NCT00868933] | 159 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| A Randomized Clinical Trial Using a Postnatal Lifestyle Modification Program to Improve Diet, Adiposity and Metabolic Outcome in Mothers With Gestational Diabetes and Their Offspring[NCT03669887] | 103 participants (Actual) | Interventional | 2018-09-12 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Abdominal VAT mass from baseline to week 12 was measured by CT scan. (NCT00752726)
Timeframe: Baseline to week 12
| Intervention | kg (Mean) |
|---|---|
| Orlistat 60 mg | -0.496 |
| Placebo | -0.351 |
VAT was measured by the computed tomography (CT) scan. (NCT00752726)
Timeframe: Baseline to week 24
| Intervention | kg (Mean) |
|---|---|
| Orlistat 60 mg | -0.630 |
| Placebo | -0.403 |
Participants were weighed at least twice until two consecutive measurements were within 0.5 kg of each other and the average of the two measurements was recorded. (NCT00752726)
Timeframe: Baseline to week 24
| Intervention | kg (Mean) |
|---|---|
| Orlistat 60 mg | -5.96 |
| Placebo | -3.91 |
The liver fat was measured by CT scan in Hounsfield Units (HU). (NCT00752726)
Timeframe: Baseline to week 24
| Intervention | Hounsfield Units (HU) (Mean) |
|---|---|
| Orlistat 60 mg | 0.06 |
| Placebo | 0.02 |
Body fat was assessed through Bioelectrical Impedance Analysis (BIA). (NCT00752726)
Timeframe: Baseline to week 24
| Intervention | Percentage (%) body fat (Mean) |
|---|---|
| Orlistat 60 mg | -1.70 |
| Placebo | -0.38 |
For Liver fat, Intrahepatic lipids (IHL) were measured by Magnetic Resonance Spectroscopy (MRS). (NCT00752726)
Timeframe: Baseline to week 24
| Intervention | Percentage (%) IHL (Mean) |
|---|---|
| Orlistat 60 mg | -0.0008 |
| Placebo | -0.0112 |
QoL scores were measured using an Impact of Weight Quality of Life (IWQoL) Questionnaire, which scored the responses at a scale of 1 to 5(1, never true, to 5, always true): QoL scales for physical function, self-esteem, sexual life, public distress, and work were evaluated, and summarized in a total score. A higher value indicated a better quality of life. (NCT00752726)
Timeframe: Baseline to week 24
| Intervention | Score on a Scale (Mean) |
|---|---|
| Orlistat 60 mg | 5.29 |
| Placebo | 8.78 |
Measurement of physical activity from Paffenbarger questionnaire. The number of caloried expended was representation of activity level: Higher calorie counts indicate higher activity (NCT00752726)
Timeframe: Baseline to week 24
| Intervention | Kilocalorie (kcal)/week (Mean) |
|---|---|
| Orlistat 60 mg | -498 |
| Placebo | 517 |
Change in total fat mass was calculated from an average of three measurements at each visit from Echo Magnetic Resonance Imaging (EchoMRI). (NCT00752726)
Timeframe: Baseline to week 24
| Intervention | kg (Mean) |
|---|---|
| Orlistat 60 mg | -4.69 |
| Placebo | -3.16 |
Waist circumference was measured against the skin, without interference from clothing, at the level midway between the lateral lower rib margin and the iliac crest in standing position. (NCT00752726)
Timeframe: Baseline to week 24
| Intervention | cm (Mean) |
|---|---|
| Orlistat 60 mg | -6.65 |
| Placebo | -4.95 |
The selectivity index (SI) was used as a measure of orlistat's ability to target abdominal VAT loss compared to total adipose tissue lost. SI was calculated using the following equation: Mean % change in VAT divided by Mean % change in total fat mass. (NCT00752726)
Timeframe: Baseline to week 24
| Intervention | Ratio (Number) |
|---|---|
| Orlistat 60 mg | 1.155 |
Body Mass index standard deviation score calculated for age and sex according to Centers for Disease Control standards. See: Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002; (246): 1-190. (NCT00001723)
Timeframe: baseline to 6 months
| Intervention | Standard Deviation Score (Mean) |
|---|---|
| Orlistat | -0.12 |
| Placebo | -0.06 |
body fat distribution measures obtained from Dual-energy X-ray Absorptiometry (DEXA) (NCT00001723)
Timeframe: baseline to 6 months
| Intervention | kg (Mean) |
|---|---|
| Orlistat | -3.2 |
| Placebo | -1.7 |
BMI is calculated in kg/m2. Change from baseline to 6 months of treatment (NCT00001723)
Timeframe: baseline to 6 months
| Intervention | kg per square meter (Mean) |
|---|---|
| Orlistat | -1.44 |
| Placebo | -0.50 |
Weight in kg (NCT00001723)
Timeframe: baseline to 6 months
| Intervention | kg (Mean) |
|---|---|
| Orlistat | -2.9 |
| Placebo | -0.6 |
Difference in change of weight in kg according to race (Non-Hispanic White versus Non-Hispanic Black) (NCT00001723)
Timeframe: baseline to 6 months
| Intervention | kg (Mean) |
|---|---|
| Orlistat - Non-Hispanic Blacks | -2.126 |
| Orlistat - Non- Hispanic Whites | -3.742 |
| Placebo - Non-Hispanic Blacks | 0.415 |
| Placebo - Non-Hispanic Whites | -1.580 |
13 reviews available for 1-anilino-8-naphthalenesulfonate and Weight Loss
| Article | Year |
|---|---|
Lipase Inhibitors for Obesity: A Review.
Topics: Adiposity; Animals; Anti-Obesity Agents; Enzyme Inhibitors; Humans; Lipase; Lipid Metabolism; Obesit | 2020 |
Practical approach to non-alcoholic fatty liver disease in patients with diabetes.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet; Gastrointestinal Microbiome; Hepatitis; Humans; Hypogly | 2015 |
Current pharmacotherapeutic concepts for the treatment of obesity in adults.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Enzyme In | 2009 |
Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy | 2009 |
Obesity pharmacotherapy: what is next?
Topics: Anti-Obesity Agents; Appetite; Drug Delivery Systems; Humans; Life Style; Lipase; Neuropeptides; Obe | 2013 |
A plate half full. Optimism about weight loss medications.
Topics: Appetite Depressants; Humans; Lipase; Obesity; Weight Loss | 2004 |
[Chronic pancreatitis. Main symptoms: chronic abdominal pain, weight loss in steatorrhea, secondary diabetes mellitus].
Topics: Abdominal Pain; Adult; Cholangiopancreatography, Endoscopic Retrograde; Chronic Disease; Diabetes Me | 2005 |
The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Dysli | 2005 |
[Pharmacotherapy in the treatment of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoid Receptor Antagonists; Clinical Trials as Topi | 2006 |
First clinical studies with orlistat: a short review.
Topics: Adult; Enzyme Inhibitors; Female; Humans; Lactones; Lipase; Male; Middle Aged; Obesity; Orlistat; Ra | 1995 |
New aspects in the management of obesity: operation and the impact of lipase inhibitors.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Humans; Lactones; Lipase; Mul | 1999 |
Why and how should adults lose weight?
Topics: Anti-Obesity Agents; Enzyme Inhibitors; Humans; Lactones; Lipase; Obesity; Orlistat; Weight Loss | 1998 |
Safe and effective management of the obese patient.
Topics: Anti-Obesity Agents; Appetite Depressants; Cognitive Behavioral Therapy; Cyclobutanes; Exercise; Gas | 1999 |
36 trials available for 1-anilino-8-naphthalenesulfonate and Weight Loss
| Article | Year |
|---|---|
The Effect of Orlistat on Sterol Metabolism in Obese Patients.
Topics: Adult; Anti-Obesity Agents; Cholesterol; Double-Blind Method; Humans; Lactones; Lipase; Obesity; Orl | 2022 |
Long-term inhibition of intestinal lipase by orlistat improves release of gut hormones increasing satiety in obese women.
Topics: Body Mass Index; Body Weight; Double-Blind Method; Female; Glucagon-Like Peptide 1; Humans; Insulin; | 2013 |
Dietary Fat Intake Modifies the Effect of a Common Variant in the LIPC Gene on Changes in Serum Lipid Concentrations during a Long-Term Weight-Loss Intervention Trial.
Topics: Adult; Aged; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diet, High-Fat; Diet, Reducing; Di | 2015 |
Dietary Fat Intake Modifies the Effect of a Common Variant in the LIPC Gene on Changes in Serum Lipid Concentrations during a Long-Term Weight-Loss Intervention Trial.
Topics: Adult; Aged; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diet, High-Fat; Diet, Reducing; Di | 2015 |
Dietary Fat Intake Modifies the Effect of a Common Variant in the LIPC Gene on Changes in Serum Lipid Concentrations during a Long-Term Weight-Loss Intervention Trial.
Topics: Adult; Aged; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diet, High-Fat; Diet, Reducing; Di | 2015 |
Dietary Fat Intake Modifies the Effect of a Common Variant in the LIPC Gene on Changes in Serum Lipid Concentrations during a Long-Term Weight-Loss Intervention Trial.
Topics: Adult; Aged; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diet, High-Fat; Diet, Reducing; Di | 2015 |
Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).
Topics: Adolescent; Adult; Aged; Benzoxazines; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; | 2010 |
Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Body Mass Index; Diet; Dose-Response Relationship, Dru | 2010 |
Effect of orlistat on the total ghrelin and leptin levels in obese patients.
Topics: Adult; Anti-Obesity Agents; Diet, Reducing; Enzyme Inhibitors; Female; Ghrelin; Humans; Lactones; Le | 2009 |
Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Adult; Caloric Restriction; Dietary Carbohydrates; Energy Met | 2011 |
Pragmatic study of orlistat 60 mg on abdominal obesity.
Topics: Abdominal Fat; Adiposity; Adult; Anti-Obesity Agents; Body Mass Index; Combined Modality Therapy; Di | 2011 |
Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial.
Topics: Adiposity; Adult; Anti-Obesity Agents; Body Mass Index; Combined Modality Therapy; Diet, Reducing; D | 2011 |
Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans.
Topics: Adult; Body Mass Index; Diet, Reducing; Dietary Carbohydrates; Dietary Sucrose; Fatty Liver; Female; | 2012 |
Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
Topics: Adolescent; Adult; Aged; Anthropometry; Anti-Obesity Agents; Blood Glucose; Blood Pressure; Combined | 2003 |
The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Enzyme Inhibitors; Fatty Liver; Fema | 2003 |
Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification.
Topics: Adult; Aged; Anti-Obesity Agents; Behavior Therapy; Cardiovascular Diseases; Combined Modality Thera | 2003 |
Lipase inhibition by orlistat: effects on gall-bladder kinetics and cholecystokinin release in obesity.
Topics: Adult; Anti-Obesity Agents; Body Weight; Cholecystokinin; Female; Gallbladder; Humans; Lactones; Lip | 2004 |
The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study.
Topics: Alleles; Diabetes Mellitus, Type 2; Disease Progression; Exercise; Female; Genetic Predisposition to | 2004 |
Influence of intense multidisciplinary follow-up and orlistat on weight reduction in a primary care setting.
Topics: Adult; Anti-Obesity Agents; Body Mass Index; Continuity of Patient Care; Diet, Reducing; Family Prac | 2005 |
Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
Topics: Adolescent; Anti-Obesity Agents; Behavior Therapy; Blood Glucose; Blood Pressure; Body Composition; | 2005 |
Influences of fat restriction and lipase inhibition on gastric emptying in obesity.
Topics: Anti-Obesity Agents; Cholecystokinin; Diet, Fat-Restricted; Diet, Reducing; Enzyme Inhibitors; Femal | 2006 |
Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.
Topics: Adult; Benzoxazines; Cholesterol; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibito | 2007 |
Effectiveness of a lifestyle modification programme in weight maintenance in obese subjects after cessation of treatment with Orlistat.
Topics: Adolescent; Adult; Albuminuria; Anti-Obesity Agents; Basal Metabolism; Blood Glucose; Blood Pressure | 2007 |
Effectiveness of a lifestyle modification programme in weight maintenance in obese subjects after cessation of treatment with Orlistat.
Topics: Adolescent; Adult; Albuminuria; Anti-Obesity Agents; Basal Metabolism; Blood Glucose; Blood Pressure | 2007 |
Effectiveness of a lifestyle modification programme in weight maintenance in obese subjects after cessation of treatment with Orlistat.
Topics: Adolescent; Adult; Albuminuria; Anti-Obesity Agents; Basal Metabolism; Blood Glucose; Blood Pressure | 2007 |
Effectiveness of a lifestyle modification programme in weight maintenance in obese subjects after cessation of treatment with Orlistat.
Topics: Adolescent; Adult; Albuminuria; Anti-Obesity Agents; Basal Metabolism; Blood Glucose; Blood Pressure | 2007 |
Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study.
Topics: Abdominal Fat; Adiponectin; Adult; Aged; Anti-Obesity Agents; Biomarkers; C-Reactive Protein; Diet, | 2008 |
Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Denmark; Diet, Reducing; Dose-Response Relationship, Drug | 1995 |
Effects of an American Heart Association step I diet and weight loss on lipoprotein lipid levels in obese men with silent myocardial ischemia and reduced high-density lipoprotein cholesterol.
Topics: Aged; Cardiology; Cholesterol, HDL; Diet; Heparin; Humans; Lipase; Lipoprotein Lipase; Lipoproteins; | 1995 |
Lipase inhibition: a novel concept in the treatment of obesity.
Topics: Adolescent; Adult; Body Mass Index; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Lac | 1993 |
Insulin and leptin concentrations in obese humans during long-term weight loss.
Topics: Adult; Biomarkers; Body Mass Index; Diet; Double-Blind Method; Enzyme Inhibitors; Female; Follow-Up | 1997 |
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
Topics: Adult; Anti-Obesity Agents; Blood Pressure; Body Mass Index; Diet, Reducing; Double-Blind Method; En | 1998 |
[Reduction of obesity and improvement in metabolic parameters by inhibition of intestinal lipases: current results with orlistat].
Topics: Adult; Aged; Austria; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Fema | 1998 |
Treatment with orlistat reduces cardiovascular risk in obese patients.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diet, Reducing; Double-Blind Me | 1998 |
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
Topics: Adult; Analysis of Variance; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Double-Blind Me | 1999 |
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
Topics: Adult; Anti-Obesity Agents; Behavior Therapy; Cardiovascular Diseases; Cholesterol, HDL; Dietary Fat | 1999 |
Orlistat in the long-term treatment of obesity in primary care settings.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Double-Blind Met | 2000 |
Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Double-Bl | 2000 |
Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns.
Topics: Adult; Anti-Obesity Agents; Body Composition; Body Constitution; Body Mass Index; Calorimetry, Indir | 2000 |
Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X.
Topics: Adult; Anti-Obesity Agents; Cholesterol, HDL; Diet, Reducing; Double-Blind Method; Female; Humans; I | 2001 |
Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.
Topics: Adult; Anti-Obesity Agents; Bile; Bile Acids and Salts; Cholesterol; Double-Blind Method; Energy Int | 2001 |
The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Belgium; Cholesterol; Cholesterol, LDL; Diet, Reducing | 2001 |
46 other studies available for 1-anilino-8-naphthalenesulfonate and Weight Loss
| Article | Year |
|---|---|
A novel multi-parametric analysis of non-invasive methods to assess animal distress during chronic pancreatitis.
Topics: Animals; Disease Models, Animal; Laparotomy; Lipase; Male; Mice; Mice, Inbred C57BL; Pain; Pancreati | 2019 |
Penicillium fellutanum lipase as a green and ecofriendly biocatalyst for depolymerization of poly (ɛ-caprolactone): Biochemical, kinetic, and thermodynamic investigations.
Topics: Caproates; Humans; Lactones; Lipase; Penicillium; Polyesters; Prospective Studies; Thermodynamics; W | 2022 |
Insulin, not glutamine dipeptide, reduces lipases expression and prevents fat wasting and weight loss in Walker 256 tumor-bearing rats.
Topics: Adipose Tissue; Animals; Cachexia; Cell Line, Tumor; Gene Expression Regulation, Enzymologic; Insuli | 2017 |
The effect of combined diet and exercise intervention on body weight and the serum GPIHBP1 concentration in overweight/obese middle-aged women.
Topics: Adipose Tissue; Biomarkers; Caloric Restriction; Cholesterol, HDL; Cholesterol, LDL; Exercise; Femal | 2017 |
Physiological response of adipocytes to weight loss and maintenance.
Topics: Adipocytes; Adiposity; Adult; Body Mass Index; Energy Metabolism; Fatty Acids; Female; Glucose; Huma | 2013 |
Increased β-oxidation with improved glucose uptake capacity in adipose tissue from obese after weight loss and maintenance.
Topics: 3-Hydroxyacyl-CoA Dehydrogenase; Adipose Tissue; Adult; Annexin A2; Caloric Restriction; Carrier Pro | 2014 |
Weight loss allows the dissection of the interaction between abdominal fat and PNPLA3 (adiponutrin) in the liver damage of obese children.
Topics: Abdominal Fat; Alanine Transaminase; Alleles; Body Mass Index; Child; Fatty Liver; Genotype; Heteroz | 2013 |
Cetilistat for the treatment of obesity.
Topics: Animals; Anti-Obesity Agents; Benzoxazines; Diabetes Mellitus, Type 2; Humans; Lipase; Obesity; Weig | 2013 |
Anti-obesity action of gingerol: effect on lipid profile, insulin, leptin, amylase and lipase in male obese rats induced by a high-fat diet.
Topics: Amylases; Animals; Anti-Obesity Agents; Blood Glucose; Catechols; Dietary Fats; Fatty Alcohols; Insu | 2014 |
Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia.
Topics: Adenocarcinoma; Adipose Tissue; Administration, Oral; Animals; Cachexia; Carcinoma, Lewis Lung; Colo | 2015 |
Effect of Bariatric Weight Loss on the Adipose Lipolytic Transcriptome in Obese Humans.
Topics: Adipose Tissue; Bariatric Surgery; Female; Humans; Lipase; Lipolysis; Male; Obesity; Sterol Esterase | 2015 |
Smart conjugated polymer nanocarrier for healthy weight loss by negative feedback regulation of lipase activity.
Topics: Animals; Anti-Obesity Agents; Drug Carriers; Lactones; Lipase; Male; Mice; Mice, Inbred ICR; Nanopar | 2016 |
Weight loss induced by bariatric surgery restores adipose tissue PNPLA3 expression.
Topics: Adipose Tissue; Adult; Aged; Austria; Bariatric Surgery; Female; Hepatocytes; Humans; Laparoscopy; L | 2017 |
PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.
Topics: Adipose Tissue; Adult; Analysis of Variance; Bariatric Surgery; Female; Humans; Lipase; Lipid Metabo | 2016 |
Should we Investigate Gastroenterology Patients for Pancreatic Exocrine Insufficiency? A Dual Centre UK Study.
Topics: Biomarkers; Clinical Enzyme Tests; Comorbidity; England; Enzyme Replacement Therapy; Exocrine Pancre | 2016 |
Trans-10, cis-12-conjugated linoleic acid does not increase body fat loss induced by energy restriction.
Topics: Adipocytes; Adipose Tissue; Adiposity; Animals; Caloric Restriction; Cell Size; Cricetinae; Drug Eva | 2008 |
The role of lipase and alpha-amylase in the degradation of starch/poly(epsilon-caprolactone) fiber meshes and the osteogenic differentiation of cultured marrow stromal cells.
Topics: Alkaline Phosphatase; alpha-Amylases; Animals; Bone Marrow Cells; Calcium; Cell Differentiation; Cel | 2009 |
[Pharmacological therapy of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Bradykinin; Cannabinoid Receptor Antagon | 2008 |
Response to fasting in an unnaturally obese carnivore, the captive European polecat Mustela putorius.
Topics: Animals; Blood Cell Count; Body Temperature; Body Weight; Cholesterol; Europe; Fasting; Female; Ferr | 2009 |
Effects of weight loss on lipid transfer proteins in morbidly obese women.
Topics: Adult; Body Mass Index; Carrier Proteins; Cholesterol Ester Transfer Proteins; Female; Humans; Lipas | 2009 |
Postprandial lipid-related metabolites are altered in dogs fed dietary diacylglycerol and low glycemic index starch during weight loss.
Topics: 3-Hydroxybutyric Acid; Animals; Cholesterol; Dietary Carbohydrates; Dietary Fats; Diglycerides; Dog | 2010 |
Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue.
Topics: Adipose Tissue; Animals; Carboxylic Ester Hydrolases; Cell Movement; Fatty Acids, Nonesterified; Lip | 2010 |
Adipose triglyceride lipase contributes to cancer-associated cachexia.
Topics: Adipose Tissue, White; Animals; Blood Glucose; Body Mass Index; Body Weight; Cachexia; Cytokines; Fa | 2011 |
Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant.
Topics: Adult; Alleles; Case-Control Studies; Diabetes Mellitus, Type 2; Disease Susceptibility; Female; Gen | 2012 |
[What effect does losing weight have on hypertension?].
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Clinical Trials as Topic; Contraindicati | 2003 |
The 'expert patient': empowerment or medical dominance? The case of weight loss, pharmaceutical drugs and the Internet.
Topics: Adult; Attitude to Health; Communication; Female; Humans; Internet; Lactones; Lipase; Male; Motivati | 2005 |
Antiobese and hypolipidemic effects of platycodin saponins in diet-induced obese rats: evidences for lipase inhibition and calorie intake restriction.
Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Cholesterol, LDL; Dietary Fats; Eating; Feces; Hypolip | 2005 |
[Effect of orlistat therapy on carbohydrate, lipid, vitamin and hormone plasma levels in obese subjects].
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Carbohydrates; Case-Control Studies; Cholesterol, HDL; Ch | 2004 |
Inhibition of pancreatic lipase by poloxamer 407 may provide an adjunct treatment strategy for weight loss.
Topics: Animals; Enzyme Inhibitors; Excipients; Fat Emulsions, Intravenous; Fats; Feces; Lipase; Mice; Obesi | 2006 |
Rimonabant: new drug. Obesity: loss of a few kilos, many questions.
Topics: Anti-Obesity Agents; Cholesterol, HDL; Diet, Reducing; Double-Blind Method; Drug Approval; Europe; E | 2006 |
Adipose triglyceride lipase and hormone-sensitive lipase protein expression is decreased in the obese insulin-resistant state.
Topics: Adipose Tissue; Adult; Biopsy; Diet, Reducing; Female; Gene Expression Regulation, Enzymologic; Huma | 2007 |
The effects of orlistat treatment interruption on weight and associated metabolic parameters.
Topics: Anti-Obesity Agents; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Humans; Lact | 2006 |
[Struggle about the best reducing diet, Fat gone by means of more fat?].
Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Body Mass Index | 2004 |
Effects of weight reduction programs on close family members.
Topics: Adult; Aged; Behavior Therapy; Combined Modality Therapy; Exercise; Family; Female; Humans; Lactones | 1994 |
Effect of prolonged exercise training without weight loss on high-density lipoprotein metabolism in overweight men.
Topics: Adult; Apolipoproteins A; Body Weight; Exercise; Humans; Kinetics; Lipase; Lipids; Lipoproteins, HDL | 1997 |
Effect of chronic amylase inhibition on pancreatic growth and acinar cell secretory function in rats.
Topics: Amylases; Animals; Carbachol; DNA; Eating; Enzyme Inhibitors; Lipase; Male; Muscarinic Agonists; Pan | 1998 |
Obesity: a time bomb to be defused.
Topics: Adult; Aged; Anti-Obesity Agents; Body Mass Index; Diabetes Mellitus; Enzyme Inhibitors; Female; Hea | 1998 |
Flushing away the fat. Weight loss during trials of orlistat was significant, but over half was due to diet.
Topics: Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Lactones; Lipase; Male; Multicenter Stu | 1998 |
Pancreatic exocrine insufficiency following pancreatic resection.
Topics: Abdominal Pain; Celiac Disease; Humans; Lipase; Pancreas; Pancreatic Diseases; Pancreatitis; Postope | 1999 |
Anti-obesity action of oolong tea.
Topics: Adipocytes; Animals; Caffeine; Cell-Free System; Dietary Fats; Eating; Female; Lipase; Lipolysis; Li | 1999 |
Orlistat: new preparation. No hurry . . .
Topics: Anti-Obesity Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lactones; Lipase; O | 1999 |
Continuous enteral feeding has an attenuating effect on the exocrine pancreas in rats.
Topics: Animals; DNA; Enteral Nutrition; Lipase; Male; Organ Size; Pancreas; Proteins; Rats; Rats, Wistar; T | 2001 |
High-density-lipoprotein metabolism during a very-low-calorie diet.
Topics: Acyltransferases; Adult; Apolipoprotein A-I; Apolipoprotein A-II; Cholesterol, HDL; Diet, Reducing; | 1992 |
Effect of pancreatectomy on plasma activities of amylase, isoamylase, lipase and trypsin-like immunoreactivity in dogs.
Topics: Amylases; Animals; Blood Glucose; Dogs; Female; Islets of Langerhans Transplantation; Isoamylase; Li | 1991 |
Relationships between the amount of weight loss and post-heparin lipoprotein lipase activity in patients with type II diabetes.
Topics: Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mel | 1991 |
Effects of weight loss and weight maintenance on the serum lipids, lipoprotein lipase and hepatic triglyceride lipase activities in obese rats.
Topics: Animals; Body Weight; Lipase; Lipids; Lipoprotein Lipase; Liver; Obesity; Rats; Rats, Inbred Strains | 1989 |